Ritu Baral
Stock Analyst at TD Cowen
(1.64)
# 3,399
Out of 5,005 analysts
36
Total ratings
36.67%
Success rate
-0.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ritu Baral
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Buy | $154 → $193 | $157.16 | +22.80% | 4 | Oct 2, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $35 → $39 | $21.80 | +78.90% | 2 | Sep 11, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $390 → $554 | $443.01 | +25.05% | 2 | Aug 26, 2025 | |
| AKRO Akero Therapeutics | Initiates: Buy | $76 | $46.10 | +64.86% | 1 | Aug 4, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Buy | $44 | $65.78 | -33.11% | 1 | Feb 5, 2025 | |
| SPRO Spero Therapeutics | Downgrades: Hold | n/a | $2.05 | - | 4 | Nov 18, 2024 | |
| ANTX AN2 Therapeutics | Downgrades: Hold | n/a | $1.30 | - | 2 | Nov 18, 2024 | |
| RNA Avidity Biosciences | Maintains: Buy | $56 → $78 | $47.00 | +65.96% | 1 | Oct 21, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $282 → $371 | $456.35 | -18.70% | 4 | Oct 21, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | n/a | $7.29 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $175 | $22.64 | +672.97% | 1 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $8.82 | - | 2 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.56 | - | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $13.10 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.23 | - | 2 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $30.14 | - | 1 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $8.23 | - | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.52 | - | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.62 | - | 2 | Jul 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $715.51 | - | 2 | Jan 12, 2018 |
Insmed
Oct 2, 2025
Maintains: Buy
Price Target: $154 → $193
Current: $157.16
Upside: +22.80%
ACADIA Pharmaceuticals
Sep 11, 2025
Maintains: Buy
Price Target: $35 → $39
Current: $21.80
Upside: +78.90%
Madrigal Pharmaceuticals
Aug 26, 2025
Maintains: Buy
Price Target: $390 → $554
Current: $443.01
Upside: +25.05%
Akero Therapeutics
Aug 4, 2025
Initiates: Buy
Price Target: $76
Current: $46.10
Upside: +64.86%
Palvella Therapeutics
Feb 5, 2025
Initiates: Buy
Price Target: $44
Current: $65.78
Upside: -33.11%
Spero Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.05
Upside: -
AN2 Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.30
Upside: -
Avidity Biosciences
Oct 21, 2024
Maintains: Buy
Price Target: $56 → $78
Current: $47.00
Upside: +65.96%
Alnylam Pharmaceuticals
Oct 21, 2024
Maintains: Buy
Price Target: $282 → $371
Current: $456.35
Upside: -18.70%
Sagimet Biosciences
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $7.29
Upside: -
Mar 22, 2023
Maintains: Outperform
Price Target: $125 → $175
Current: $22.64
Upside: +672.97%
Nov 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $8.82
Upside: -
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.56
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $13.10
Upside: -
Jul 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.23
Upside: -
Jun 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $30.14
Upside: -
Mar 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $8.23
Upside: -
Jun 29, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.52
Upside: -
Jul 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $0.62
Upside: -
Jan 12, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $715.51
Upside: -